India, July 1 -- Mesoblast Limited (MESO) rose 12.40 percent to $12.24 on Tuesday after announcing it reached alignment with the FDA on requirements to file a Biologics License Application for Revascor, aimed at treating ischemic heart failure patients with reduced ejection fraction and inflammation.
Shares opened at $12.00, moved between $11.72 and $12.50 on the Nasdaq, and traded 254,644 shares, above the 206,195 averages, as investors welcomed the FDA progress.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....